| Project Detail |
Revolutionising pharmaceutical continuous manufacturing
The pharmaceutical industry is experiencing growing demand and anticipates periods of chaotic increases due to diseases and pandemics resulting from climate change. Despite efforts to promote continuous manufacturing, which promises cheaper, more sustainable, adaptable, and faster drug production, many substances’ poor mechanical properties render them unsuitable for this process. Supported by the Marie Sklodowska-Curie Actions (MSCA) programme, the ManCoProc project seeks to address this challenge by developing a universal drug-excipient co-processing (CP) platform that leverages crystallisation and co-precipitation techniques to overcome the limitations posed by the poor mechanical properties of numerous drugs. The project will use cutting-edge technology and techniques to analyse and optimise this innovative process.
Pharmaceutical industry is starting to adopt the approach of continuous manufacturing, with as few unit operations as possible, to deliver drug products in a faster, robust, cheaper and sustainable way.
Poor mechanical properties of many drug substances are a hindrance to this, making them unsuitable for direct compression into tablets without additional operations. This challenge can be solved by co-processing: joining the particles of such drugs to the particles of inactive substances known as excipients (e.g. lactose), normally used for tablets production.
The aim of this project is to develop a universal drug-excipient co-processing (CP) platform based on surface crystallization or co-precipitation. A CP method in a milifluidic device will be optimised with a range of drugs with differing physicochemical properties. The relationships between them, as well as excipient properties, parameters of the method and structural and functional characteristics of the obtained composites will be thoroughly investigated. To this end, cutting edge techniques will be employed to analyse particle size, morphology, dissolution and mechanical behaviour. To demonstrate improved manufacturability, the prototype CP material will be used for direct compression, and the tablets quality will be evaluated according to European Pharmacopeia requirements.
The project will enable the researcher to achieve professional maturity in the field of particle engineering, allowing to employ her skills both in academia and in pharmaceutical industry. The results of the research will have commercialisation value, being of interest to companies as a potential new platform in (pre)formulation portfolio. The project will contribute to the body of evidence informing the decisions of regulators on pharmaceutical co-processing. In the long term, such impact should advance the transformation towards continuous manufacturing of affordable, available and sustainable drug products. |
